Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD 337 (dexnefopam) in fibromyalgia
NCT00377039Phase 2Completed
- Sponsor
- Nxera Pharma
- Start
- Aug 2006
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibromyalgia (FM) comparing AD 337 with Placebo (2 arms). Primary endpoint: Fibromyalgia Impact Questionnaire Total Score at 4 weeks. Started Aug 2006; status: completed.
02
Drugs
dexnefopam
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT00377039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00377039.